Bluesight acquires Protenus so as to add privateness monitoring options
Bluesight has acquired Protenus, a supplier of healthcare compliance analytics platforms, to reinforce its drug diversion platform and introduce important options for monitoring affected person privateness.
This helps enhance safety for healthcare organizations and the communities they serve.
The acquisition merges Bluesight's intelligence and Protenus' specialization in compliance and danger administration, with a mixed platform.
Bluesight co-founder and CEO Kevin MacDonald mentioned: “Protenus is on the forefront of AI & analytics in healthcare compliance, addressing the crucial want for compliance expertise that helps healthcare organizations meet the to fulfill and even exceed the best high quality of care and security requirements.
“We have now lengthy admired their merchandise, experience and crew, and this acquisition is a transformative step in Bluesight's journey to increase our compliance capabilities. By becoming a member of forces, we can ship a really complete answer that addresses a few of immediately's most urgent healthcare challenges and delivers even higher worth to our clients.”
Protenus gives scalable danger discount options to healthcare organizations utilizing synthetic intelligence. This strategy helps the organizations obtain protected and high quality affected person outcomes.
Achieve entry to probably the most complete firm profiles in the marketplace, powered by GlobalData. Save hours of analysis. Achieve aggressive benefit.
Firm Profile – Free Pattern
Your obtain e-mail will arrive shortly
We have now confidence within the distinctive high quality of our firm profiles. Nonetheless, we would like you to take advantage of helpful resolution for your corporation. That's why we give you a free pattern that you would be able to obtain by submitting the shape under.
By GlobalData
Since its founding in 2014, the corporate has been serving to healthcare organizations within the US handle dangers related to their enterprise operations.
Protenus co-founder and CEO Nick Culbertson mentioned: “We’re thrilled to hitch the Bluesight platform, which can assist speed up our mission to supply healthcare organizations with the required instruments to guard their sufferers and their to safeguard your individual fame.
“Partnering with Bluesight will improve our skill to innovate and meet the altering wants of our clients, and permit us to additional capitalize on the rising demand for our compliance capabilities. Collectively we are going to create a platform that not solely mitigates danger, but additionally units new requirements for excellence in healthcare compliance and past.”
